首页 | 本学科首页   官方微博 | 高级检索  
     

协同刺激分子程序性死亡受体1及其配体1在脑胶质瘤中的表达及其临床意义
引用本文:李建红,马丽莉,张丽娜. 协同刺激分子程序性死亡受体1及其配体1在脑胶质瘤中的表达及其临床意义[J]. 肿瘤研究与临床, 2020, 0(1): 32-35
作者姓名:李建红  马丽莉  张丽娜
作者单位:长治医学院附属和济医院神经外科;长治医学院附属和平医院病理科;长治医学院免疫学教研室
基金项目:山西省卫生和计划生育委员会科研项目(2017160)。
摘    要:目的探讨协同刺激分子程序性死亡受体1(PD-1)及程序性死亡受体配体1(PD-L1)在人脑胶质瘤中的表达及其临床意义。方法收集2013年1月至2017年12月长治医学院附属和济医院70例脑胶质瘤术后蜡块标本及35例正常脑组织蜡块标本。采用免疫组织化学SP法检测PD-1、PD-L1在胶质瘤组织及正常脑组织中的表达。分析两者表达与患者临床病理特征之间的关系以及PD-1、PD-L1两者在胶质瘤组织中表达的相关性。结果PD-1、PD-L1在胶质瘤组织中的阳性表达率分别为69%(48/70)、62%(43/70),均高于其在正常脑组织中的阳性表达率[29%(10/35)、31%(11/35)],差异均有统计学意义(χ2值分别为15.099、8.407,均P<0.05)。高级别胶质瘤中PD-1、PD-L1的阳性表达率分别为81%(30/37)、73%(27/37),均高于低级别胶质瘤中的阳性表达率[55%(18/33)、49%(16/33)],差异均有统计学意义(χ2值分别为5.699、4.415,均P<0.05)。不同性别、年龄、肿瘤最大径分层患者间PD-1、PD-L1阳性表达率差异均无统计学意义(均P>0.05)。胶质瘤组织中PD-1与PD-L1蛋白的表达呈正相关(r=0.372,P=0.002)。结论PD-1、PD-L1可能在胶质瘤的发生、发展过程中相互作用,有望成为评估胶质瘤发生、发展的生物学新指标。

关 键 词:脑肿瘤  神经胶质瘤  程序性死亡受体1  程序性死亡受体配体1  免疫组织化学

Expressions of coordinated stimulating molecular programmed death 1 and its ligand 1 in brain glioma and their clinical significances
Li Jianhong,Ma Lili,Zhang Lina. Expressions of coordinated stimulating molecular programmed death 1 and its ligand 1 in brain glioma and their clinical significances[J]. Cancer Research and Clinic, 2020, 0(1): 32-35
Authors:Li Jianhong  Ma Lili  Zhang Lina
Affiliation:(Department of Neurosurgery,Heji Hospital Affiliated to Changzhi Medical College,Changzhi 046011,China;Department of Pathology,Heping Hospital Affiliated to Changzhi Medical College,Changzhi 046000,China;Department of Immunology,Changzhi Medical College,Changzhi 046000,China)
Abstract:Objective To analyze the expressions of coordinated stimulating molecular programmed death 1(PD-1)and programmed death ligand 1(PD-L1)in human glioma and their clinical significances.Methods A total of 70 postoperative paraffin specimens of brain glioma and 35 normal brain tissues in Heji Hospital Affiliated to Changzhi Medical College from January 2013 to December 2017 were collected.The expressions of PD-1 and PD-L1 in 70 glioma tissues and 35 normal brain tissues were detected by immunohistochemical SP method.The relationship between the expressions of PD-1 and PD-L1 and their correlation with the clinicopathological features were analyzed.Results The positive expression rates of PD-1 and PD-L1 in glioma tissues were 69%(48/70)and 62%(43/70),respectively,which were higher than those in normal brain tissues[29%(10/35),31%(11/35)],the differences were statistically significant(χ2 values were 15.099 and 8.407,both P<0.05).The positive expression rates of PD-1 and PD-L 1 in high-grade glioma were 81%(30/37)and 73%(27/37),respectively,which were higher than those in low-grade glioma[55%(18/33)and 49%(16/33)],the differences were statistically significant(χ2 values were 5.699 and 4.415,both P<0.05).There was no significant difference in the positive expression rates of PD-1 and PD-L1 among patients with different sex,age and maximum tumor diameter(all P>0.05).There was a positive correlation between the expressions of PD-1 and PD-L1 proteins in glioma tissues(r=0.372,P=0.002).Conclusions The PD-1 and PD-L1 may become new biological indicators for evaluating the occurrence and development of glioma.
Keywords:Brain neoplasms  Glioma  Programmed death 1  Programmed death ligand 1  Immunohistochemistry
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号